InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
1
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the complete record of transactions filed by Dexter Susan, 首席技术官. Director active across 1 company, notably Sonnet BioTherapeutics Holdings, Inc.. Cumulatively, 8 disclosures have been recorded. Breakdown: 1 buy · 0 sell. Total volume traded: €6k. Activity tracked since 25 May 2021. The latest transaction was disclosed on 14 June 2023 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Dexter Susan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报8 总计
9,643 股Common StockSEC:0001493152-25-026068:0
8,000 股Common StockSEC:0001641172-25-019779:0
1,452 股Common StockSEC:0001493152-24-048958:0
10,000 股@ US$0.7020.5% 占其流量Common StockSEC:0001493152-23-021430:0
标准退出：2023年9月12日 (T+90)
14,627 股Common StockSEC:0001493152-23-005468:0
14,627 股Common StockSEC:0001493152-22-036321:0
63,104 股Common StockSEC:0001493152-22-009481:0
10,145 股@ US$1.5166.0% 占其流量Common StockSEC:0001493152-21-013203:0
8 条申报中的 8 条
About Dexter Susan
Susan Dexter is the Chief Technical Officer at Sonnet BioTherapeutics Holdings, Inc. She is responsible for the company's technological initiatives, ensuring innovation and efficiency in processes. Her expertise in the biopharmaceutical field is crucial for the development of new therapies.
